Moreover, circulating serum PD-L1 was suggested to be a biomarker for predicting immune checkpoint inhibitor response, particularly to the blockade of PD-1 and CTLA-4 in malignant melanoma and multiple myeloma (Wang et al., 2015; Zhou et al., 2017). The gene discussed is CTLA4; the disease is plasma cell myeloma.